Advertisement

Topics

Mixed Results with Novel Agent in PSC (CME/CE)

08:30 EDT 16 Apr 2018 | MedPageToday

(MedPage Today) -- NGM282 didn't reduce ALP, but had other benefits in primary sclerosing cholangitis

Original Article: Mixed Results with Novel Agent in PSC (CME/CE)

NEXT ARTICLE

More From BioPortfolio on "Mixed Results with Novel Agent in PSC (CME/CE)"

Advertisement
Quick Search
Advertisement
Advertisement